Cargando…

Clinical outcomes of patients with giant cell arteritis treated with tocilizumab in real-world clinical practice: decreased incidence of new visual manifestations

BACKGROUND: Placebo-controlled clinical trials have demonstrated the efficacy of tocilizumab (TCZ) for remission maintenance and glucocorticoid sparing in patients with giant cell arteritis (GCA). However, limited data exist on the effectiveness and safety of TCZ for GCA in real-world clinical pract...

Descripción completa

Detalles Bibliográficos
Autores principales:	Unizony, Sebastian, McCulley, Timothy J., Spiera, Robert, Pei, Jinglan, Sidiropoulos, Paris N., Best, Jennie H., Birchwood, Christine, Pavlov, Andrey, Stone, John H.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2021
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7789742/ https://www.ncbi.nlm.nih.gov/pubmed/33407817 http://dx.doi.org/10.1186/s13075-020-02377-8

Ejemplares similares

Design of the Tocilizumab in Giant Cell Arteritis Trial
por: Unizony, Sebastian H., et al.
Publicado: (2013)

Adverse Events in Giant Cell Arteritis and Rheumatoid Arthritis Patient Populations: Analyses of Tocilizumab Clinical Trials and Claims Data
por: Gale, Sara, et al.
Publicado: (2019)

Outcomes during and after long-term tocilizumab treatment in patients with giant cell arteritis
por: Matza, Mark A, et al.
Publicado: (2023)

Treatment failure in giant cell arteritis
por: Unizony, Sebastian H, et al.
Publicado: (2021)

Glucocorticoid Dosages and Acute‐Phase Reactant Levels at Giant Cell Arteritis Flare in a Randomized Trial of Tocilizumab
por: Stone, John H., et al.
Publicado: (2019)

New-onset versus relapsing giant cell arteritis treated with tocilizumab: 3-year results from a randomized controlled trial and extension
por: Stone, John H, et al.
Publicado: (2021)

Risk of Potential Glucocorticoid-Related Adverse Events in Patients with Giant Cell Arteritis: Results from a USA-Based Electronic Health Records Database
por: Best, Jennie H., et al.
Publicado: (2019)

Benchmarking tocilizumab use for giant cell arteritis
por: Conway, Richard, et al.
Publicado: (2022)

Comment on: Benchmarking tocilizumab use for giant cell arteritis
por: Janagan, Shalini, et al.
Publicado: (2022)

Serum osteopontin: a biomarker of disease activity and predictor of relapsing course in patients with giant cell arteritis. Potential clinical usefulness in tocilizumab-treated patients
por: Prieto-González, Sergio, et al.
Publicado: (2017)

Profile of tocilizumab and its potential in the treatment of giant cell arteritis
por: Mollan, Susan Patricia, et al.
Publicado: (2018)

Vision loss in patients with giant cell arteritis treated with tocilizumab
por: Amsler, Jennifer, et al.
Publicado: (2021)

Giant Cell Arteritis With Chronic Bronchitis Successfully Treated With Tocilizumab
por: Ohta, Ryuichi, et al.
Publicado: (2023)

Comparative Cost per Response for 4 Clinical Endpoints with Tocilizumab Monotherapy vs Adalimumab Monotherapy in a Head-to-Head Randomized Double-Blind Superiority Trial (ADACTA) in Patients with Rheumatoid Arthritis
por: Best, Jennie H., et al.
Publicado: (2020)

Quantitative ultrasound to monitor the vascular response to tocilizumab in giant cell arteritis
por: Seitz, Luca, et al.
Publicado: (2021)

Tocilizumab for relapsing and remitting giant cell arteritis: a case series
por: Saha, Pratyasha, et al.
Publicado: (2022)

Estimating the Cost of Illness of Giant Cell Arteritis in the United States
por: Babigumira, Joseph B., et al.
Publicado: (2017)

A phase 3 randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of sarilumab in patients with giant cell arteritis
por: Schmidt, Wolfgang A., et al.
Publicado: (2023)

The Effects of Treatment on Body Mass Index in Giant Cell Arteritis: A Post Hoc Analysis of the GiACTA Trial
por: Patel, Naomi J., et al.
Publicado: (2021)

Giant cell arteritis: Its ophthalmic manifestations
por: Hayreh, Sohan Singh
Publicado: (2021)

Improvement of Treg immune response after treatment with tocilizumab in giant cell arteritis
por: Samson, Maxime, et al.
Publicado: (2021)

Is Tocilizumab Effective and Safe in Polymyalgia Rheumatica and Giant-Cell Arteritis With Polymyalgia Rheumatica?
por: Farinango, Michelle, et al.
Publicado: (2022)

Health-related quality of life in patients with giant cell arteritis treated with tocilizumab in a phase 3 randomised controlled trial
por: Strand, Vibeke, et al.
Publicado: (2019)

Healthcare Costs of Potential Glucocorticoid-Associated Adverse Events in Patients with Giant Cell Arteritis
por: Best, Jennie H, et al.
Publicado: (2019)

Clinical Images: Pulmonary Arteritis in Clinically Occult Aneurysmal Giant Cell Arteritis
por: Johnson, Victoria L, et al.
Publicado: (2021)

Long-term efficacy and safety of tocilizumab in giant cell arteritis and large vessel vasculitis
por: Evans, Jobie, et al.
Publicado: (2016)

55. A case for continuing tocilizumab beyond 12 months in giant cell arteritis?
por: Ming, Caroline, et al.
Publicado: (2019)

Tocilizumab-associated posterior reversible encephalopathy syndrome in giant-cell arteritis – case report
por: Butryn, Michaela, et al.
Publicado: (2021)

Tocilizumab in visual involvement of giant cell arteritis: a multicenter study of 471 patients
por: Loricera, Javier, et al.
Publicado: (2022)

Widespread headache as the first clinical manifestation of giant cell arteritis in patients affected by polymyalgia rheumatica
por: Manzo, Ciro
Publicado: (2016)

The Role of Multimodality Imaging in Monitoring Disease Activity and Therapeutic Response to Tocilizumab in Giant Cell Arteritis
por: Conticini, Edoardo, et al.
Publicado: (2020)

Assessment of the efficacy and safety of tocilizumab in patients over 80 years old with giant cell arteritis
por: de Boysson, Hubert, et al.
Publicado: (2021)

Atypical Cogan's Syndrome Mimicking Giant Cell Arteritis Successfully Treated with Early Administration of Tocilizumab
por: Hara, Kazusato, et al.
Publicado: (2021)

Tongue necrosis secondary to giant cell arteritis, successfully treated with tocilizumab: a case report
por: Cho, Young Min, et al.
Publicado: (2023)

Interstitial Lung Disease as an Initial Manifestation of Giant Cell Arteritis
por: Konishi, Chisato, et al.
Publicado: (2017)

Stroke as the First Clinical Manifestation of Takayasu's Arteritis
por: Pereira, Vanessa Caldeira, et al.
Publicado: (2014)

Tocilizumab for faster and safer remission of Takayasu’s arteritis
por: Liao, Hua, et al.
Publicado: (2022)

Simultaneous Pleural and Pericardial Effusion as First Clinical Manifestations of Giant Cell Arteritis: A Case Report
por: Georgakopoulou, Vasiliki E, et al.
Publicado: (2020)

Long-term treatment with tocilizumab in giant cell arteritis: efficacy and safety in a monocentric cohort of patients
por: Regola, Francesca, et al.
Publicado: (2020)

Stevens Johnson Syndrome in a Patient with Giant Cell Arteritis During Short Term Tocilizumab Therapy
por: Venkateswaran, Niranjani, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_k69hi6od12kbafvssbo6maqsng